The study found that long-term therapy with ACE inhibitors (OR 0.75; CI: 0.65–0.87), ARBs (OR 0.71; CI: 0.57–0.89), or β-blockers (OR 0.78; CI: 0.67–0.92) was correlated with a significantly lower risk of incident AF compared to calcium-channel blockers. The gene discussed is ACE; the disease is atrial fibrillation.